-
Subject Areas on Research
-
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
-
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
-
A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.
-
A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
-
Active chemotherapy for metastatic stromal cell tumor of the testis.
-
Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection.
-
Adult testicular sarcoma: presentation, evaluation, and treatment.
-
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
-
Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93).
-
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
-
Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.
-
Cerebral atrophy in an infant following treatment with ifosfamide.
-
Epirubicin and ifosfamide in metastatic breast cancer.
-
Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion.
-
Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study.
-
Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm.
-
Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents.
-
Giant thoracic liposarcoma treated with induction chemotherapy followed by surgical resection.
-
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
-
High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
-
Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
-
Ifosfamide enantiomers: pharmacokinetics in children.
-
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
-
Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.
-
Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide.
-
Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.
-
Pancreatoblastoma in a teenage patient.
-
Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy.
-
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
-
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
-
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
-
Progressive glomerular toxicity of ifosfamide in children.
-
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
-
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
-
Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors.
-
Sickness behavior clustering in children with cancer.
-
Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer.
-
Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide.
-
The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.